Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

80.17
Delayed Data
As of 4:00pm ET
 -1.04 / -1.28%
Today’s Change
63.76
Today|||52-Week Range
86.27
+11.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$106.1B

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Contact Information

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City California 94404
P:(650) 574-3000
Investor Relations:

Employees

Shareholders

Mutual fund holders41.40%
Other institutional37.19%
Individual stakeholders1.18%

Top Executives

John F. MilliganPresident, Chief Executive Officer & Director
Kevin B. YoungChief Operating Officer
Robin L. WashingtonChief Financial Officer & Executive Vice President
Norbert W. BischofbergerChief Scientific Officer & Executive VP-Research
William A. LeeExecutive Vice President-Research